Our analysis of targeted genes revealed that high-grade NSCLC has a low percentage of actionable genes with LEVEL_1 evidence, and EGFR mutations are the most actionable with LEVEL_1 evidence. This evidence concerns the gene EGFR and non-small cell lung carcinoma.